Dr. Daniel Chang is a nationally and internationally recognized expert in radiotherapy for GI malignancies. His primary research interest is in advanced radiotherapy techniques, primarily with stereotactic body radiotherapy (SBRT). He has led several studies investigating and establishing the efficacy and safety for SBRT for these diseases for liver and pancreatic tumors. His other research interests include normal tissue tolerances, quality of life after radiotherapy, and combining radiotherapy with targeted agents. In addition, he has a strong interest in the use of radiotherapy, particularly in combination with systemic agents, in patients with metastatic disease. Another area of interest is in health care utilization for patients with metastatic disease and using machine learning and other approaches to optimize care during the end-of-life period.
Dr. Chang is interested in developing novel modalities and technologies for delivering radiotherapy. He previously led the FDA trial that led to approval of PET-guided radiotherapy, which in broader terms, is called Biology-guided radiotherapy. In addition, he has experience with MR-guided radiotherapy, and he is interested in exploring the role of particle therapy and heave ion radiotherapy.
Dr. Chang received his MD from Wayne State University in 2002 and completed his residency in Radiation Oncology at the University of Florida in Gainesville, Florida in 2007. He then joined the Department of Radiation Oncology at Stanford University from 2007-2022, having previously served as residency program director from 2012-2017 and the Vice Chair of Clinical Operations from 2017-2022 where he was also the Sue and Bob McCollum Professor in Radiation Oncology.
Dr. Chang is a member of the American Society of Radiation Oncology (ASTRO), American Radium Society (ARS), and the American Society of Clinical Oncology (ASCO). He serves on the scientific committee for ASTRO, ASCO, and GI ASCO. He has authored or co-authored over 190 peer-reviewed publications for journals including Journal of Clinical Oncology, Journal of the National Cancer Institute, Clinical Cancer Research, Radiology, International Journal of Radiation Oncology, Biology, and Physics, Radiotherapy and Oncology, and Cancer. He served as the senior editor for the GI section of the International Journal of Radiation Oncology, Biology, and Physics from 2013-2017 and is currently on the editorial board for Practical Radiation Oncologysince 2020. He served on the Hepatobiliary Panel for the National Cancer Comprehensive Network (NCCN) guidelines from 2013-2022, helping to shape national guidelines for the work-up, diagnosis, and treatment of patients with hepatobiliary cancers. He is currently the track chair for the GI track for the ASTRO Annual Meeting Scientific Committee. He also serves on the Education Committee for the Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Track for the ASCO annual meeting starting in 2023.
Areas of Interest
- SBRT for treatment of pancreatic and liver tumors
- Radiotherapy for gastrointestinal malignancies (esophagogastric, pancreatic hepatobiliary, anorectal)
- Radiotherapy for oligometastatic disease and combining with novel systemic targeted therapy
- Novel radiotherapy technologies
- Focusing on advanced radiotherapy technologies for treating gastrointestinal (GI) malignancies for pancreatic and liver tumors, particularly stereotactic body radiotherapy (SBRT).
Honors & Awards
- 2017 Sue and Bob McCollum Endowed Professorship
- 2016 Stanford University Department of Radiation Oncology Richard T Hoppe Leadership Award
- 2015 Association of Residents in Radiation Oncology Educator of the Year Award
- 2014 Stanford University Department of Radiation Oncology – Golden Nugget Award
- 2008 Stanford University Department of Radiation Oncology The Henry S. Kaplan Memorial Prize for Teaching
- 2008 Liu Bie Ju Cha and Family Fellow, Stanford University Medical Center
- 2007 Roentgen Resident/Fellow Research Award, Radiological Society of North America
- 2006 The American Radium Society Young Oncology Essay Award
- 2005 University of Florida Annual Research Seminar Resident Talken Award
- MD, Wayne State University, 2002
- Residency in Radiation Oncology, University of Florida, Gainesville, FL, 2007
- Board Certification: American Board of Radiology (Radiation Oncology), 2008
- Assistant Professor Radiation Oncology, Stanford University 2007-2012
- Associate Professor Radiation Oncology, Stanford University 2012-2017
- Professor Radiation Oncology, Stanford University 2017-2-22
- Sue and Bob McCollum Professor in Radiation Oncology, Stanford University 2017-2-22
04/01/21 - 03/31/26, National Cancer Institute, R01 Research Grant 1R01CA256890 Chang (co-Investigator):
Leveraging deep learning for markerless motion management in radiation therapy.
Selected From Over 190 Peer-reviewed Publications
Presented nationally and internationally including China, Korea, Japan, Taiwan, Brazil, Singapore, the Philippines, Australia, and France
- Miller JA, Toesca DAS, Baclay JRM, Vitzthum LK, Dubrowski P, Pollom EL, Chang DT Pancreatic stereotactic body radiation therapy with or without hypofractionated elective nodal irradiation. Int J Radiat Oncol Biol Phys. 2022 Jan 1;112(1):131-1
- Bibault JE, Chang DT, Xing L Development and validation of a model to predict survival in colorectal cancer using a gradient-boosted machine. Gut. 2021 May;70(5):884-8
- Benson KRK, Aggarwal S, Carter JN, von Eyben R, Pradhan P, Prionas ND, Bui JL, Soltys SG, Hancock SL, Gensheimer MF, Koong AC, Chang, DT Predicting Survival for Patients with Metastatic Disease. Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):52-60
- Gensheimer MF, Henry AS, Wood DJ, Hastie TJ, Aggarwal S, Dudley SA, Pradhan P, Banerjee I, Cho E, Ramchandran K, Pollom E, Koong AC, Rubin DL, Chang DT. Automated survival prediction in metastatic cancer patients using high-dimensional electronic medical record data. J Natl Cancer Inst 2019 Jun 1;111(6):568-5
- Toesca DAS, Jeffrey RB, von Eyben R, Pollom EL, Poullos PD, Poultsides GA, Fisher GA, Visser BC, Koong AC, Chang DT Predicting Pancreatic Cancer Resectability And Outcomes Based On An Objective Quantitative Scoring System. Pancreas. 48(5):622-628, May/June 201